Skip to main content
. Author manuscript; available in PMC: 2013 May 13.
Published in final edited form as: AJR Am J Roentgenol. 2013 Mar;200(3):475–483. doi: 10.2214/AJR.12.9049

TABLE 3.

Currently Approved Cancer Agents With Target Molecules on Host Immune Cells (Immune Modulators)

Category Agent Class Molecular Target FDA-Approved Indication

Immune modulators Ipilimumab (Yervoy, Bristol-Myers Squibb) mAb CTLA Melanoma

Note—FDA = Food and Drug Administration, mAb = monoclonal antibody, CTLA = cytotoxic T-lymphocyte antigen.